-+ 0.00%
-+ 0.00%
-+ 0.00%

Takeda's Oveporexton Demonstrates Safety and Efficacy in Global Phase 3 Studies, Paving Way For New Narcolepsy Treatment

Benzinga·07/14/2025 07:19:42
Listen to the news
  • Both Phase 3 Studies Met all Primary and Secondary Endpoints Demonstrating Statistically Significant Improvements Across Symptoms at All Doses, Building Upon Phase 2b Results
  • Oveporexton was Generally Well-Tolerated in Phase 3 Safety Profile Takeda is Rapidly Advancing Regulatory Submissions and Launch Preparedness with the Aim to Bring Oveporexton to People Living with Narcolepsy Type 1 as Quickly as Possible
  • these Results Mark a Major Advancement Toward Transforming the Standard of Care by Addressing the Underlying Cause of Narcolepsy Type 1